Targeting the 8-oxodG Base Excision Repair Pathway for Cancer Therapy.

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Genomic integrity is essential for preventing mutations and diseases like cancer.
• The Base Excision Repair (BER) pathway is crucial for repairing oxidative DNA damage.
• 8-oxoguanine glycosylase 1 (OGG1) is a key enzyme in the BER pathway, excising 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) lesions.

Purpose of the Study:

• To provide an updated perspective on small-molecule inhibitors targeting the 8-oxodG-BER pathway.
• To highlight the potential of BER inhibitors in expanding cancer treatment strategies.
• To serve as a reference for researchers in the field.

Main Methods:

• Review of scientific literature on BER pathway and OGG1.
• Analysis of small-molecule inhibitors targeting the 8-oxodG-BER pathway.
• Exploration of synthetic lethal interactions and tumor-specific dependencies.

Main Results:

• BER inhibitors show promise in cancer therapy by increasing sensitivity to existing treatments.
• Targeting the 8-oxodG-BER pathway offers a strategy for selective cancer cell targeting.
• Small-molecule inhibitors represent a growing area of cancer drug development.

Conclusions:

• Inhibitors of the 8-oxodG-BER pathway are a promising avenue for novel cancer therapies.
• Exploiting DNA repair mechanisms can lead to targeted cancer treatments with reduced side effects.
• Further research into BER inhibitors could significantly advance oncology treatment strategies.